S&P 500   3,984.32 (+0.83%)
DOW   32,492.70 (+0.77%)
QQQ   307.14 (+0.38%)
AAPL   157.29 (-0.07%)
MSFT   270.45 (-0.65%)
META   199.57 (+0.89%)
GOOGL   102.50 (+1.26%)
AMZN   98.44 (+0.75%)
TSLA   190.36 (+3.88%)
NVDA   259.85 (+0.33%)
NIO   9.13 (+4.34%)
BABA   82.72 (+2.12%)
AMD   96.29 (-0.54%)
T   18.55 (+0.32%)
F   11.59 (+3.67%)
MU   58.37 (+1.27%)
CGC   1.97 (+5.91%)
GE   91.95 (+2.26%)
DIS   95.37 (+1.22%)
AMC   4.31 (+0.94%)
PFE   40.62 (-0.47%)
PYPL   74.99 (+2.43%)
NFLX   304.29 (-0.28%)
S&P 500   3,984.32 (+0.83%)
DOW   32,492.70 (+0.77%)
QQQ   307.14 (+0.38%)
AAPL   157.29 (-0.07%)
MSFT   270.45 (-0.65%)
META   199.57 (+0.89%)
GOOGL   102.50 (+1.26%)
AMZN   98.44 (+0.75%)
TSLA   190.36 (+3.88%)
NVDA   259.85 (+0.33%)
NIO   9.13 (+4.34%)
BABA   82.72 (+2.12%)
AMD   96.29 (-0.54%)
T   18.55 (+0.32%)
F   11.59 (+3.67%)
MU   58.37 (+1.27%)
CGC   1.97 (+5.91%)
GE   91.95 (+2.26%)
DIS   95.37 (+1.22%)
AMC   4.31 (+0.94%)
PFE   40.62 (-0.47%)
PYPL   74.99 (+2.43%)
NFLX   304.29 (-0.28%)
S&P 500   3,984.32 (+0.83%)
DOW   32,492.70 (+0.77%)
QQQ   307.14 (+0.38%)
AAPL   157.29 (-0.07%)
MSFT   270.45 (-0.65%)
META   199.57 (+0.89%)
GOOGL   102.50 (+1.26%)
AMZN   98.44 (+0.75%)
TSLA   190.36 (+3.88%)
NVDA   259.85 (+0.33%)
NIO   9.13 (+4.34%)
BABA   82.72 (+2.12%)
AMD   96.29 (-0.54%)
T   18.55 (+0.32%)
F   11.59 (+3.67%)
MU   58.37 (+1.27%)
CGC   1.97 (+5.91%)
GE   91.95 (+2.26%)
DIS   95.37 (+1.22%)
AMC   4.31 (+0.94%)
PFE   40.62 (-0.47%)
PYPL   74.99 (+2.43%)
NFLX   304.29 (-0.28%)
S&P 500   3,984.32 (+0.83%)
DOW   32,492.70 (+0.77%)
QQQ   307.14 (+0.38%)
AAPL   157.29 (-0.07%)
MSFT   270.45 (-0.65%)
META   199.57 (+0.89%)
GOOGL   102.50 (+1.26%)
AMZN   98.44 (+0.75%)
TSLA   190.36 (+3.88%)
NVDA   259.85 (+0.33%)
NIO   9.13 (+4.34%)
BABA   82.72 (+2.12%)
AMD   96.29 (-0.54%)
T   18.55 (+0.32%)
F   11.59 (+3.67%)
MU   58.37 (+1.27%)
CGC   1.97 (+5.91%)
GE   91.95 (+2.26%)
DIS   95.37 (+1.22%)
AMC   4.31 (+0.94%)
PFE   40.62 (-0.47%)
PYPL   74.99 (+2.43%)
NFLX   304.29 (-0.28%)
Most-Downgraded Stocks  
NYSE:PFE

Pfizer - PFE Stock Forecast, Price & News

$40.67
-0.14 (-0.34%)
(As of 03/21/2023 10:34 AM ET)
Add
Compare
Today's Range
$40.50
▼
$40.91
50-Day Range
$39.39
▼
$47.85
52-Week Range
$39.23
▼
$56.32
Volume
3.20 million shs
Average Volume
23.68 million shs
Market Capitalization
$229.56 billion
P/E Ratio
7.42
Dividend Yield
4.03%
Price Target
$50.38

Pfizer MarketRank™ Forecast

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
23.2% Upside
$50.38 Price Target
Short Interest
Healthy
0.68% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.21mentions of Pfizer in the last 14 days
Based on 46 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.15%
From $3.30 to $3.80 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.22 out of 5 stars

Medical Sector

15th out of 988 stocks

Pharmaceutical Preparations Industry

4th out of 482 stocks

See Top Rated MarketRank™ Stocks Here

PFE stock logo

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

March 21, 2023 | marketbeat.com
Why did Sarepta Therapeutics Stock Plummet? (PFE)
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
March 18, 2023 | marketbeat.com
MarketBeat Week in Review – 3/13 - 3/17 (PFE)
The first triple witching day of 2023 is a fitting way to end a wild week. As you take some time to relax, here are some of our most popular stories this week
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
March 15, 2023 | marketbeat.com
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock
March 8, 2023 | marketbeat.com
Schrodinger is an AI-Powered Drug Discovery Developer to Watch (PFE)
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
March 2, 2023 | dividendstocks.com
AbbVie Stock: ABBV Overview and Dividend Potential (PFE)
March 1, 2023 | marketbeat.com
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11 (PFE)
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its
February 28, 2023 | marketbeat.com
FDA panel narrowly backs Pfizer RSV vaccine for older adults
Federal health advisers have narrowly backed an experimental vaccine from Pfizer that could become the first shot to protect older adults against the respiratory illness known as RSV
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
February 27, 2023 | marketbeat.com
Stocks open higher on Wall Street following last week’s rout
Stocks are opening higher, clawing back some of the losses from their worst week since early December
February 24, 2023 | marketbeat.com
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
February 22, 2023 | marketbeat.com
Four Undervalued Healthcare Stocks for 2023 (PFE)
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
March 21, 2023 | americanbankingnews.com
Pfizer (NYSE:PFE) Price Target Lowered to $44.00 at Wells Fargo & Company
March 21, 2023 | americanbankingnews.com
Jefferies Financial Group Comments on Pfizer Inc.'s Q1 2023 Earnings (NYSE:PFE)
March 20, 2023 | finance.yahoo.com
UPDATE 1-Moderna expects to price its COVID vaccine at about $130 in the US
March 20, 2023 | benzinga.com
Insiders Selling Pfizer And 2 Other Stocks
March 19, 2023 | finance.yahoo.com
1 Top Healthcare Stock That Could Make You Richer in the Next Decade
March 18, 2023 | seekingalpha.com
Pfizer developing new Nurtec ODT packaging following recall - Bloomberg
March 17, 2023 | finance.yahoo.com
Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates
March 17, 2023 | finance.yahoo.com
Pfizer Working To Develop New Packaging For Migraine Drug Over Child Safety, Poisoning Concerns
March 17, 2023 | finance.yahoo.com
FDA Advisory Committee Votes Favoring Pfizer's COVID-19 Pill Paxlovid
March 17, 2023 | finance.yahoo.com
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
March 17, 2023 | finance.yahoo.com
WHO expects to declare end to pandemic sometime in 2023 as virus becomes more like seasonal flu
March 17, 2023 | finance.yahoo.com
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote
March 17, 2023 | finance.yahoo.com
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
March 17, 2023 | seekingalpha.com
Pfizer, Astellas' Xtandi meets main goal in phase 3 trial for prostate cancer subtype
March 17, 2023 | americanbankingnews.com
UBS Group Analysts Give Pfizer (NYSE:PFE) a $45.00 Price Target
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Company Calendar

Ex-Dividend for 3/3 Dividend
1/26/2023
Last Earnings
1/31/2023
Dividend Payable
3/03/2023
Today
3/20/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:PFE
CUSIP
71708110
CIK
78003
Web
www.pfizer.com
Phone
(212) 733-2323
Fax
302-655-5049
Employees
83,000
Year Founded
1849

Price Target and Rating

Average Stock Price Forecast
$50.38
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+23.4%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
14 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.48
Trailing P/E Ratio
7.45
Forward P/E Ratio
12.37
P/E Growth
1.34
Net Income
$31.37 billion
Net Margins
31.27%
Pretax Margin
34.62%
Return on Equity
42.03%
Return on Assets
19.55%

Debt

Debt-to-Equity Ratio
0.34
Current Ratio
1.22
Quick Ratio
1.00

Sales & Book Value

Annual Sales
$100.33 billion
Price / Sales
2.29
Cash Flow
$7.76 per share
Price / Cash Flow
5.26
Book Value
$17.09 per share
Price / Book
2.39

Miscellaneous

Outstanding Shares
5,619,080,000
Free Float
5,616,265,000
Market Cap
$229.31 billion
Optionable
Optionable
Beta
0.64

Social Links


Key Executives

  • Albert Bourla
    Chairman & Chief Executive Officer
  • David M. Denton
    Chief Financial Officer & Executive Vice President
  • Mikael Dolsten
    Co-Chief Scientific Officer & President-Research
  • Maria Rivas
    Chief Medical Affairs Officer
  • Aida Habtezion
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PFE Stock - Frequently Asked Questions

Should I buy or sell Pfizer stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View PFE analyst ratings or view top-rated stocks.

What is Pfizer's stock price forecast for 2023?

14 equities research analysts have issued 12-month target prices for Pfizer's shares. Their PFE share price forecasts range from $40.00 to $75.00. On average, they anticipate the company's share price to reach $50.38 in the next year. This suggests a possible upside of 23.4% from the stock's current price.
View analysts price targets for PFE or view top-rated stocks among Wall Street analysts.

How have PFE shares performed in 2023?

Pfizer's stock was trading at $51.24 at the start of the year. Since then, PFE stock has decreased by 20.4% and is now trading at $40.81.
View the best growth stocks for 2023 here.

When is Pfizer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PFE earnings forecast.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, January, 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The biopharmaceutical company earned $24.30 billion during the quarter, compared to analysts' expectations of $24.40 billion. Pfizer had a trailing twelve-month return on equity of 42.03% and a net margin of 31.27%. Pfizer's revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the company earned $1.08 EPS.
Read the conference call transcript.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Friday, December 9th. Investors of record on Friday, January 27th will be paid a dividend of $0.41 per share on Friday, March 3rd. This represents a $1.64 annualized dividend and a yield of 4.02%. The ex-dividend date is Thursday, January 26th. This is an increase from the stock's previous quarterly dividend of $0.40.
Read our dividend analysis for PFE.

What ETFs hold Pfizer's stock?

ETFs with the largest weight of Pfizer (NYSE:PFE) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), iShares U.S. Healthcare ETF (IYH), iShares Core High Dividend ETF (HDV), Vanguard Health Care ETF (VHT), VanEck Durable High Dividend ETF (DURA), IQ Healthy Hearts ETF (HART) and VanEck Pharmaceutical ETF (PPH).

Is Pfizer a good dividend stock?

Pfizer (NYSE:PFE) pays an annual dividend of $1.64 per share and currently has a dividend yield of 4.09%. PFE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 29.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PFE will have a dividend payout ratio of 43.16% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PFE.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided EPS guidance of $3.25-$3.45 for the period, compared to the consensus estimate of $4.38. The company issued revenue guidance of $67.0-$71.0 billion, compared to the consensus revenue estimate of $74.23 billion.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of retail and institutional investors. Top institutional investors include Moneta Group Investment Advisors LLC (2.87%), Geode Capital Management LLC (1.95%), Morgan Stanley (1.42%), Charles Schwab Investment Management Inc. (1.31%), Norges Bank (1.10%) and Dimensional Fund Advisors LP (0.75%). Insiders that own company stock include Alexander R Mackenzie, Douglas M Lankler, Jennifer B Damico, John D Young, Pfizer Inc, Ronald E Blaylock and William R Carapezzi Jr.
View institutional ownership trends.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $40.81.

How much money does Pfizer make?

Pfizer (NYSE:PFE) has a market capitalization of $229.31 billion and generates $100.33 billion in revenue each year. The biopharmaceutical company earns $31.37 billion in net income (profit) each year or $5.48 on an earnings per share basis.

How many employees does Pfizer have?

The company employs 83,000 workers across the globe.

Does Pfizer have any subsidiaries?
The following companies are subsidiares of Pfizer: AH Robins LLC, AHP Manufacturing B.V., Agouron Pharmaceuticals LLC, Alpharma Pharmaceuticals LLC, American Food Industries LLC, Amplyx Pharmaceuticals, Amplyx Pharmaceuticals Inc., Anacor Pharmaceuticals, Anacor Pharmaceuticals Inc., Angiosyn, Arena, Array BioPharma, Array BioPharma Inc., BIND Therapeutics Inc., Bamboo Therapeutics, Bamboo Therapeutics Inc., Baxter International - Marketed Vaccines, BioRexis, Bioren, Blue Whale Re Ltd., C.P. Pharmaceuticals International C.V., CICL Corporation, COC I Corporation, Catapult Genetics, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Coley Pharmaceutical Group Inc., Covx, Cyanamid de Argentina S.A., Cyanamid de Colombia S.A., Distribuidora Mercantil Centro Americana S.A., Encysive Pharmaceuticals, Encysive Pharmaceuticals Inc., Esperion Therapeutics, Excaliard Pharmaceuticals, Farminova Produtos Farmaceuticos de Inovacao Lda., FoldRx Pharmaceuticals LLC, Foldrx Pharmaceuticals, Fort Dodge Manufatura Ltda., G. D. Searle & Co. Limited, G. D. Searle International Capital LLC, GI Europe Inc., GI Japan Inc., GenTrac Inc., Genetics Institute LLC, Hospira, Hospira Adelaide Pty Ltd, Hospira Australia Pty Ltd, Hospira Benelux BVBA, Hospira Holdings (S.A.) Pty Ltd, Hospira Inc., Hospira Limited, Hospira Philippines Inc., Hospira Pte. Ltd., Hospira Puerto Rico LLC, Hospira UK Limited, Hospira Worldwide LLC, Hospira Zagreb d.o.o., ICAgen, Idun Pharmaceuticals, InnoPharma, InnoPharma Inc., International Affiliated Corporation LLC, John Wyeth & Brother Limited, King Pharmaceuticals Holdings LLC, King Pharmaceuticals LLC, King Pharmaceuticals Research and Development LLC, Laboratoires Pfizer S.A., Laboratorios Pfizer Ltda., Laboratorios Wyeth LLC, Laboratorios Wyeth S.A., Laboratórios Pfizer Lda., MTG Divestitures LLC, Mayne Pharma IP Holdings (Euro) Pty Ltd, Medivation, Medivation Field Solutions LLC, Medivation LLC, Medivation Neurology LLC, Medivation Prostate Therapeutics LLC, Medivation Services LLC, Medivation Technologies LLC, Monarch Pharmaceuticals LLC, Neusentis Limited, NextWave Pharmaceuticals, P-D Co. LLC, PAH USA IN8 LLC, PBG Puerto Rico LLC, PF Argentum Acquisition ULC, PF Consumer Healthcare Holdings LLC, PF Consumer Healthcare Holdings US Inc., PF Czech Republic Holdings B.V., PF Finland Holdings B.V., PF OFG Ireland 2 B.V., PF OFG South Korea 1 B.V., PF OFG South Korea 2 B.V., PF PR Holdings C.V., PF PRISM C.V., PF PRISM Holdings B.V., PF PRISM IMB B.V., PFE Wyeth-Ayerst (Asia) LLC, PFIZER (VIETNAM) LIMITED COMPANY, PHIVCO Corp., PHIVCO Holdco S.à r.l., PIMB OFG Spain Holding S.L., PRISM Holdings B.V., PT. Pfizer Indonesia, Parke Davis & Company LLC, Parke Davis Limited, Parkedale Pharmaceuticals Inc., Peak Enterprises LLC, Pfizer, Pfizer (China) Research and Development Co. Ltd., Pfizer (Malaysia) Sdn Bhd, Pfizer (Perth) Pty Ltd, Pfizer (Thailand) Limited, Pfizer (Wuhan) Research and Development Co. Ltd., Pfizer AB, Pfizer AG, Pfizer AS, Pfizer Afrique de L'Ouest, Pfizer Anti-Infectives AB, Pfizer ApS, Pfizer Asia Manufacturing Pte. Ltd., Pfizer Australia Holdings B.V., Pfizer Australia Holdings Pty Limited, Pfizer Australia Investments Pty Ltd, Pfizer Australia Pty Ltd, Pfizer B.V., Pfizer Biopharma Egypt LLC, Pfizer Biopharmaceuticals Egypt LLC, Pfizer Bolivia S.A., Pfizer Canada ULC / Pfizer Canada SRI, Pfizer Chile S.A., Pfizer Cia. Ltda., Pfizer Colombia Spinco I LLC, Pfizer Consumer Healthcare, Pfizer Cork Limited, Pfizer Corporation Austria Gesellschaft m.b.H., Pfizer Corporation Hong Kong Limited, Pfizer Corporation S. de R.L., Pfizer Croatia d.o.o., Pfizer Deutschland GmbH, Pfizer Development B.V., Pfizer Development LLC, Pfizer Development LP, Pfizer Development Services (UK) Limited, Pfizer East India B.V., Pfizer Eastern Investments B.V., Pfizer Europe MA EEIG, Pfizer Export B.V., Pfizer Export Company, Pfizer Finance Share Service (Dalian) Co. Ltd., Pfizer France International Investments, Pfizer Free Zone Panama S. de R.L., Pfizer Global Holdings B.V., Pfizer Global Supply Japan Inc., Pfizer Global Trading, Pfizer Gulf FZ-LLC, Pfizer H.C.P. Corporation, Pfizer Health AB, Pfizer Health Solutions Inc., Pfizer Healthcare India Private Limited, Pfizer Healthcare Ireland, Pfizer Hellas A.E., Pfizer Himalaya Holdings Coöperatief U.A., Pfizer Holding France, Pfizer Holdings Corporation, Pfizer Holdings International Corporation, Pfizer Holdings International Luxembourg (PHIL) Sarl, Pfizer Inc., Pfizer Innovations AB, Pfizer Innovations LLC, Pfizer International LLC, Pfizer International Operations, Pfizer Investment Capital Unlimited Company, Pfizer Investment Co. Ltd., Pfizer Ireland PFE Holding 1 LLC, Pfizer Ireland PFE Holding 2 LLC, Pfizer Ireland Pharmaceuticals, Pfizer Ireland Ventures Unlimited Company, Pfizer Italia S.r.l., Pfizer Japan Inc., Pfizer Laboratories (Pty) Limited, Pfizer Laboratories Limited, Pfizer Leasing Ireland Limited, Pfizer Leasing UK Limited, Pfizer Limited, Pfizer Luxco Holdings SARL, Pfizer Luxembourg Global Holdings S.à r.l., Pfizer Luxembourg SARL, Pfizer MAP Holding Inc., Pfizer Manufacturing Austria G.m.b.H., Pfizer Manufacturing Belgium N.V., Pfizer Manufacturing Deutschland GmbH, Pfizer Manufacturing Deutschland Grundbesitz GmbH & Co. KG, Pfizer Manufacturing Holdings LLC, Pfizer Manufacturing Ireland Unlimited Company, Pfizer Manufacturing LLC, Pfizer Manufacturing Services, Pfizer Medicamentos Genericos e Participacoes Ltda., Pfizer Mexico Holding B.V., Pfizer New Zealand Limited, Pfizer North America Services LLC, Pfizer OTC B.V., Pfizer Overseas LLC, Pfizer Oy, Pfizer PFE AsiaPac Holding B.V., Pfizer PFE CIA. Ltda., Pfizer PFE Eastern Investments B.V., Pfizer PFE Global Holdings B.V., Pfizer PFE Pharmaceuticals Israel Holding LLC, Pfizer PFE Pharmaceuticals Israel Ltd., Pfizer PFE Service Company Holding B.V., Pfizer PFE Spain B.V., Pfizer PFE UK Holding 4 LP, Pfizer PFE İlaçları Anonim Şirketi, Pfizer Pakistan Limited, Pfizer Pharm Algerie, Pfizer Pharma GmbH, Pfizer Pharma PFE GmbH, Pfizer Pharmaceutical (Wuxi) Co. Ltd., Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC), Pfizer Pharmaceuticals Global B.V., Pfizer Pharmaceuticals Israel Ltd., Pfizer Pharmaceuticals Korea Limited, Pfizer Pharmaceuticals Science and Technology Co. Ltd., Pfizer Pigments Inc., Pfizer Polska Sp. z.o.o., Pfizer Private Limited, Pfizer Production LLC, Pfizer Products Inc., Pfizer Products India Private Limited, Pfizer R&D Holding B.V., Pfizer R&D Japan G.K., Pfizer R&D UK Limited, Pfizer Research (NC) Inc., Pfizer Romania SRL, Pfizer S.A., Pfizer S.A., Pfizer S.A. de C.V., Pfizer S.A.S., Pfizer S.G.P.S. Lda., Pfizer S.L., Pfizer S.R.L., Pfizer SA (Belgium), Pfizer SRB d.o.o., Pfizer Saudi Limited, Pfizer Service Company BVBA, Pfizer Service Company Ireland Unlimited Company, Pfizer Shared Services Unlimited Company, Pfizer Shareholdings Intermediate SARL, Pfizer Singapore Holding Pte. Ltd., Pfizer Specialties Limited, Pfizer Trading Polska sp.z.o.o., Pfizer Transactions LLC, Pfizer Tunisie SA, Pfizer Vaccines LLC, Pfizer Venezuela S.A., Pfizer Ventures (US) LLC, Pfizer Ventures LLC, Pfizer Worldwide Services Unlimited Company, Pfizer Zona Franca S.A., Pfizer spol. s r.o., Pharmacia, Pharmacia & Upjohn Company LLC, Pharmacia & Upjohn LLC, Pharmacia Brasil Ltda., Pharmacia Hepar LLC, Pharmacia Inter-American LLC, Pharmacia International B.V., Pharmacia LLC, Pharmacia Limited, PowderMed, Purepac Pharmaceutical Holdings LLC, ReViral, Redvax, Renrall LLC, Rinat Neuroscience, Rinat Neuroscience Corp., Roerig S.A., Searle Laboratorios Lda., Serenex, Servicios P&U S. de R.L. de C.V., Shiley LLC, Sinergis Farma-Produtos Farmaceuticos Lda., Solinor LLC, Sugen LLC, Tabor LLC, Therachon, Trillium Therapeutics, Trillium Therapeutics ULC, Trillium Therapeutics USA LLC, Upjohn Laboratorios Lda., Vicuron Holdings LLC, W-L LLC, Warner Lambert, Warner Lambert del Uruguay S.A., Warner-Lambert Company GmbH, Warner-Lambert Company LLC, Wyeth Ayerst Inc., Wyeth Ayerst S.à r.l., Wyeth Biopharma, Wyeth Farma S.A., Wyeth Holdings LLC, Wyeth Industria Farmaceutica Ltda., Wyeth LLC, Wyeth Lederle S.r.l., Wyeth Pakistan Limited, Wyeth Pharmaceuticals FZ-LLC, Wyeth Pharmaceuticals LLC, Wyeth Subsidiary Illinois Corporation, Wyeth Whitehall Export GmbH, Wyeth-Ayerst (Asia) LLC, Wyeth-Ayerst International LLC, and Wyeth-Ayerst Promotions Limited.
Read More
How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The official website for the company is www.pfizer.com. The biopharmaceutical company can be reached via phone at (212) 733-2323 or via fax at 302-655-5049.

This page (NYSE:PFE) was last updated on 3/21/2023 by MarketBeat.com Staff